956100-48-4Relevant academic research and scientific papers
Α 7 as intranuclear hydroxynicotinic acetylcholine receptor quinuclidines compd.
-
Paragraph 0590; 0591, (2018/10/03)
PROBLEM TO BE SOLVED: To provide ligands for the nicotinic α-7 receptor used for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.SOLUTION: The disclosure provides compounds of the specified formula I, including their salts, and compositions and methods using the compounds.
Isoquinolin-3-Ylurea Derivatives
-
Paragraph 0697; 0781; 0782, (2013/04/24)
The invention relates to isoquinolin-3-ylurea derivatives of formula (I) wherein R1 represents (C1-C3)alkyl, (C1-C3)haloalkyl or cyclopropyl, R4 represents H and the substituents R2 and R3 and R5 have the meanings disclosed in the specification; and to the salts of such compounds. These compounds are useful for the prevention or the treatment of bacterial infections.
ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES
-
Page/Page column 108, (2011/10/13)
The invention relates to isoquinolin-3-ylurea derivatives of formula (I) wherein R1 represents (C1-C3)alkyl, (C1-C3)haloalkyl or cyclopropyl, R4 represents H and the substituents R2 and R3 and R5 have the meanings disclosed in the specification; and to the salts of such compounds. These compounds are useful for the prevention or the treatment of bacterial infections.
SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS
-
Page/Page column 17; 28; 35-36, (2008/06/13)
The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein: R1, R2, Z1, t, and ring A are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of JNK, such as diabetes, the method comprising administering to a mammal an effective amount of a compound of formula (I).
